|
1.
|
|
6 p, 1.1 MB |
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study
/
Nahi, Hareth (Karolinska Institute. Department of Medicine) ;
Usmani, Saad Z. (Memorial Sloan Kettering Cancer Center) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
van de Donk, Niels W C J (Department of Hematology. Vrije Universiteit Amsterdam) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Plesner, Torben (Vejle Hospital and University of Southern Denmark) ;
Bandyopadhyay, Nibedita (Janssen Research & Development. LLC) ;
Hellemans, Peter (Janssen Research & Development) ;
Tromp, Brenda (Janssen Research & Development. LLC) ;
Nnane, Ivo (Janssen Research & Development. LLC) ;
Zemlickis, Donna (Janssen Research & Development. LLC) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
Moreau, Philippe (University Hospital Hôtel-Dieu (Nantes, França))
2023 -  10.1080/10428194.2022.2148221
Leukemia and Lymphoma, Vol. 64 Núm. 2 (2023) , p. 468-472
|
|
|
2.
|
|
15 p, 3.7 MB |
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
/
Botta, Cirino (Clínica Universidad de Navarra) ;
Perez, Cristina (Clínica Universidad de Navarra) ;
Larrayoz, Marta (Clínica Universidad de Navarra) ;
Puig, Noemí (Hospital Universitario de Salamanca) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre) ;
Termini, Rosalinda (Clínica Universidad de Navarra) ;
Goicoechea, Ibai (Clínica Universidad de Navarra) ;
Rodriguez, Sara (Clínica Universidad de Navarra) ;
Zabaleta, Aintzane (Clínica Universidad de Navarra) ;
Lopez, Aitziber (Clínica Universidad de Navarra) ;
Sarvide, Sarai (Clínica Universidad de Navarra) ;
Blanco, Laura (Clínica Universidad de Navarra) ;
Papetti, Daniele Marco (Department of Informatics. University of Milano-Bicocca) ;
Nobile, M.S. (Biostatistics and Bioimaging Centre-B4) ;
Besozzi, Daniela (Biostatistics and Bioimaging Centre-B4) ;
Gentile, Massimo (Department of Oncohematology. "Annunziata" Hospital) ;
Correale, Pierpaolo (Great Metropolitan Hospital "Riuniti" of Reggio Calabria) ;
Siragusa, Sergio (Department of Health Promotion. University of Palermo) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Garcia, Maria Esther (Hospital Universitario de Cabueñes (Gijón)) ;
Sureda, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
de Arriba, Felipe (Instituto Murciano de Investigación Biosanitaria) ;
Ríos-Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Moraleda, José María (Instituto Murciano de Investigación Biosanitaria) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Hernández, Miguel T. (Hospital Universitario de Canarias (Illes Canàries)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Illes Balears)) ;
Palomera, Luís (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Pérez-Montaña, Albert (Hospital Universitari Son Espases (Illes Balears)) ;
Goldschmidt, Hartmut (Department of Internal Medicine V. University of Heidelberg) ;
Avet-Loiseau, Hervé (IUC-T Oncopole) ;
Roccaro, Aldo (Department of Hematology. ASST Spedali Civili di Brescia) ;
Orfao, Alberto (Universidad de Salamanca. Departament de Medicina) ;
Martinez-Lopez, Joaquín (Hospital Universitario 12 de Octubre) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Mateos, M. V (Hospital Universitario de SalamancaBiomedica de Salamanca (IBSAL). Centro de Investigación del Cancer (IBMCC-USAL. CSIC)) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Martinez Climent, Juan-José (Clínica Universidad de Navarra) ;
Paiva, Bruno (Clínica Universidad de Navarra)
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). [...]
2023 - 10.1038/s41467-023-41562-6
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 5825
|
|
|
3.
|
|
13 p, 471.4 KB |
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial
/
Dimopoulos, Meletios (National and Kapodistrian University of Athens) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nahi, Hareth (Department of Medicine. Karolinska University) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Bahlis, Nizar J. (University of Calgary) ;
Usmani, S. Z (Memorial Sloan Kettering Cancer Center) ;
Rabin, Neil (Department of Haematology. University College London Hospitals NHS Trust) ;
Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas) ;
Suzuki, Kenshi (Department of Hematology. Japanese Red Cross Medical Center) ;
Plesner, Torben (University of Southern Denmark) ;
Yoon, Sung Soo (Department of Internal Medicine. Seoul National University) ;
Ben Yehuda, Dina (Hematology Department. Hebrew University) ;
Richardson, Paul G. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Goldschmidt, Hartmut (Heidelberg University Hospital (Alemanya)) ;
Reece, Donna (Department of Medical Oncology and Hematology. Princess Margaret Cancer Centre) ;
Ahmadi, Tahamtan (Genmab US (Estats Units d'Amèrica)) ;
Qin, Xiang (Janssen Research & Development (Xina)) ;
Garvin Mayo, Wendy (Janssen Research & Development (Estats Units d'Amèrica)) ;
Gai, Xue (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carey, Jodi (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carson, Robin (Janssen Research & Development (Estats Units d'Amèrica)) ;
Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
PURPOSEWith the initial analysis of POLLUX at a median follow-up of 13. 5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2023 - 10.1200/JCO.22.00940
Journal of Clinical Oncology, Vol. 41 Núm. 8 (october 2023) , p. 1590-1599
|
|
|
4.
|
|
10 p, 496.7 KB |
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma : IKEMA subgroup analysis
/
Facon, Thierry (Lille University Hospital) ;
Moreau, Philippe (University of Nantes) ;
Martin, Thomas G. (University of California San Francisco) ;
Spicka, Ivan (Charles University and General Hospital, Prague, Czech Republic) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Koh, Youngil (Seoul National University Hospital, South Korea) ;
Lim, Andrew (Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia) ;
Mikala, Gabor (South Pest Central Hospital, Budapest, Hungary) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Yağci, Münci (Gazi University, Ankara, Turkey) ;
Cavo, Michele (Bologna University School of Medicine, Italy) ;
Yong, Kwee (University College Hospital, London, UK) ;
Risse, Marie Laure (Sanofi R&D, Vitry-Sur-Seine, France) ;
Asset, Gaëlle (Sanofi R&D, Chilly-Mazarin, France) ;
Schwab, Sandrine (Sanofi R&D, Chilly-Mazarin, France) ;
Martinez, Gracia (Hospital das Clínicas de São Paulo, Brazil)
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM). [...]
2022 - 10.1002/hon.3038
Hematological Oncology, Vol. 40 Núm. 5 (december 2022) , p. 1020-1029
|
|
|
5.
|
|
12 p, 1.6 MB |
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
/
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Hebraud, Benjamin (Institut Universitaire du Cancer de Toulouse-Oncopole) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Colin, Anne-Laurène (Ser Centre Hospitalier et Universitaire de Toulouse) ;
Ríos Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Hulin, Cyrille (Department of Hematology. Hôpital Haut-Lévêque) ;
Blanchard, María Jesús (Hospital Ramón y Cajal) ;
Caillot, Denis (Hôpital du Bocage) ;
Sureda, Anna (Universitat de Barcelona) ;
Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ;
Arnulf, Bertrand (Hôpital St-Louis) ;
Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ;
Macro, Margaret (Centre Hospitalier et Universitaire de Caen) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Belhadj, Karim (Centre Hospitalier et Universitaire Henri Mondor) ;
Lahuerta, J. J (Clínica Universidad de Navarra) ;
Garelik, M.Brigid (Bristol-Myers Squibb Company) ;
Bladé, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Objective: Providing the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens in transplant-eligible NDMM. [...]
2023 - 10.3389/fonc.2023.1197340
Frontiers in Oncology, Vol. 13 (2023) , p. 1197340
|
|
|
6.
|
|
18 p, 862.2 KB |
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
/
Chari, Ajai (Mount Sinai School of Medicine, USA) ;
Askari, Elham (Hospital Universitario Fundación Jiménez Díaz) ;
Caers, Jo (Centre Hospitalier Universitaire de Liège, Belgium) ;
Costa, Luciano J. (University of Alabama at Birmingham, USA) ;
Hilder, Brandi W. (Janssen Research & Development, Spring House, USA) ;
Krishnan, Amrita (City of Hope Comprehensive Cancer Center, Duarte, USA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Minnema, Monique C. (University Utrecht, Netherlands) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pillarisetti, Kodandaram (Janssen Research & Development, Spring House, USA) ;
Van De Donk, Niels W.C.J. (Vrije Universiteit Amsterdam, Netherlands) ;
Rodríguez-Otero, Paula (Clínica Universidad de Navarra)
What is this summary about? This plain language summary describes the results of a phase 1 research study (or clinical trial) called MonumenTAL-1 published in the New England Journal of Medicine in December 2022. [...]
2023 - 10.2217/fon-2023-0332
Future oncology (London, England), Vol. 19 Núm. 27 (september 2023) , p. 1823-1840
|
|
|
7.
|
|
8 p, 1.0 MB |
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
/
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center) ;
Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K (Winship Cancer Institute. Emory University) ;
Martin, Thomas (University of California San Francisco) ;
Rosinol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud) ;
Benboubker, Lotfi (Hôpital Bretonneau) ;
Mateos, Maria-Victoria (University Hospital de Salamanca) ;
Popat, Rakesh (University College London Hospitals) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Sidana, Surbhi (Stanford University of Medicine) ;
Delforge, Michele (University of Leuven) ;
Pei, Lixia (Janssen Research & Development) ;
Trancucci, Danielle (Janssen Research & Development) ;
Olyslager, Yunsi (Janssen Research & Development) ;
Uhlar, Clarissa (Janssen Research & Development) ;
Stephenson, Tara (Janssen Research & Development) ;
Rampelbergh, Rian Van (Janssen Research & Development) ;
Banerjee, Arnob (Janssen Research & Development) ;
Kobos, Rachel (Janssen Research & Development) ;
Usmani, Saad Z (Levine Cancer Institute-Atrium Health)
What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. [...]
2023 - 10.2217/fon-2023-0171
Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818
|
|
|
8.
|
|
9 p, 1.2 MB |
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma
/
Gonzalez-Montes, Yolanda (Universitat de Girona) ;
Rodriguez-Romanos, Rocío (Universitat de Girona) ;
Villavicencio, Alicia (Universitat de Girona) ;
Osca-Gelis, Gemma (Universitat de Girona) ;
González-Bártulos, Marta (Universitat de Girona) ;
Llopis, Francesca (Universitat de Girona) ;
Clapes, Victòria (Hospital Universitari de Bellvitge) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sureda, Anna (Hospital Universitari de Bellvitge) ;
Escoda, Lourdes (Universitat Rovira i Virgili) ;
Sarrà, Josep (Universitat Rovira i Virgili) ;
Garzó, Ana (Universitat de Girona) ;
Lloveras, Natàlia (Universitat de Girona) ;
Díez, Isabel (Universitat de Girona) ;
Granada, Isabel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gallardo, David (Universitat de Girona)
Immune dysfunction in patients with multiple myeloma (MM) affects both the innate and adaptive immune system. Molecules involved in the immune checkpoint pathways are essential to determine the ability of cancer cells to escape from the immune system surveillance. [...]
2023 - 10.3389/fimmu.2023.1158105
Frontiers in immunology, Vol. 14 (april 2023)
|
|
|
9.
|
|
11 p, 396.3 KB |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics
/
Richardson, Paul G.. (Department of Medical Oncology. Harvard Medical School) ;
Schjesvold, Fredrik (University of Oslo) ;
Weisel, Katja (University Medical Center Hamburg-Eppendorf) ;
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Anderson, Larry D. (University of Texas Southwestern Medical Center) ;
White, Darrell (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Sonneveld, Pieter (Erasmus MC Cancer Institute) ;
Engelhardt, Monika (Universitätsklinikum Freiburg) ;
Jenner, Matthew (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Corso, Alessandro (Hospital of Legnano) ;
Dürig, Jan (University Hospital Essen (Alemanya)) ;
Pavic, Michel (Centre Hospitalier Universitaire De Sherbrooke) ;
Salomo, Morten (Copenhagen University Hospital) ;
Beksac, Meral (Ankara University) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lindsay, Jindriska (East Kent Hospitals University NHS Foundation Trust) ;
Liberati, Anna Marina (University of Perugia) ;
Galli, Monica (Ospedale Papa Giovanni XXIII. U.O. di Ematologia) ;
Robak, Pawel (Medical University of Lodz) ;
Larocca, Alessandra (A.O.U. Citta della Salute e della Scienza di Torino) ;
Yagci, Munci (Gazi University Medical Faculty) ;
Vural, Filiz (Ege University) ;
Kanate, Abraham (West Virginia University) ;
Jiang, Ruiyun (Bristol Myers Squibb) ;
Grote, Lara (Bristol Myers Squibb) ;
Peluso, Teresa (Celgene International Sàrl. a Bristol-Myers Squibb Company) ;
Dimopoulos, Meletios (National and Kapodistrian University of Athens)
Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. [...]
2022 - 10.1111/ejh.13706
European Journal of Haematology, Vol. 108 Núm. 1 (january 2022) , p. 73-83
|
|
|
10.
|
|
16 p, 1.0 MB |
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma : A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
/
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Dimopoulos, Meletios (National and Kapodistrian University) ;
Schjesvold, Fredrik (University of Oslo) ;
Beksac, Meral (Ankara Üniversitesi Tip Fakültes) ;
Facon, Thierry (Hôpital Claude Huriez CHU de Lille) ;
Dhanasiri, Sujith (Celgene International Sàrl. a Bristol-Myers Squibb Company (Suïssa)) ;
Guo, Shien (Evidera) ;
Mu, Yutian (Evidera) ;
Hong, Kevin (Bristol Myers Squibb) ;
Gentili, Christian (Bristol Myers Squibb) ;
Galli, Mónica (ASST Papa Giovanni XXIII) ;
Yagci, Munci (Gazi University) ;
Larocca, Alessandra (University of Torino) ;
Richardson, Paul (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Weisel, Katja (University Medical Center Hamburg-Eppendorf (Alemanya))
Introduction: A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and dexamethasone (PVd) for treating relapsed/refractory MM. [...]
2023 - 10.1016/j.clml.2023.10.009
Clinical Lymphoma, Myeloma & Leukemia, 2023
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
